Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7303359 in Geographic Atrophy
NCT04615325Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7303359 in geographic atrophy (GA) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Ocular Adverse Events up to 12 weeks, Percentage of Participants With Systemic Adverse Events up to 12 weeks and 5 more. Started Dec 2020; status: completed.
02
Drugs
RO7303359
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04615325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615325.